| 0.11 | 0.36% |
| SLXP Salix Pharmaceuticals Ltd. | Trade It Now | | NASDAQ |
| |
Market Cap 1.604B Book Value 7.093 EBITDA -27.2M Year Low 7.40 Year High 32.03 PEG Ratio 14.42 EPS -0.884 P/B Ratio 4.32 Short Ratio 3.30 Index Membership S&P 600 SmallCap S&P  Sector Healthcare Industry Drug Related Products Open 30.74 High 30.91 Low 30.27 Last Close 30.64 Volume 671.7 K Target Price 41.33 Current EPS -0.884 This Year EPS 0.05 Next Year EPS 1.48 This Year PE 612.80 Next Year PE 20.70 Salix Pharmaceuticals Ltd.1700 Perimeter Park Drive Morrisville,
NC 27560-8404 United States - Map
Phone: 919-862-1000
Fax: 919-862-1095
Web Site: VisitType: Stock | | Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. |
Company Summary more  Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or short-term therapy for adults; Azasan, a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis; Anusol-HC and Proctocort, the hydrocortisone creams and suppositories for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and inflammatory conditions; Pepcid and Diuril oral suspensions, which are used for gastrointestinal indications that include the treatment of duodenal ulcer, benign gastric ulcer, and gastro esophageal reflux diseases; and Colazal capsules for the treatment of ulcerative colitis. In addition, Salix has products under development for the treatment of hepatic encephalopathy and irritable bowel syndrome, HIV-associated diarrhea, gastroenterology, and ulcerative proctitis or proctosigmoiditis. It has collaboration agreements with aaiPharma LLC; Alfa Wassermann S.P.A.; Biorex Laboratories Limited; Cedars—Sinai Medical Center; Clinical Development Capital Partnership; Dr. Falk Pharma GmbH; King Pharmaceuticals, Inc.; Lupin, Ltd.; Merck & Co., Inc.; Napo Pharmaceuticals, Inc.; Norgine B.V.; and Wilmington Pharmaceuticals, LLC. The company was founded in 1989 and is headquartered in Morrisville, North Carolina. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. The company’s marketing products include Xifaxan tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; MoviPrep, a liquid polyethylene glycol-salt bowel cleansing product; Visicol and OsmoPrep tablets for cleansing of the colon as a preparation for colonoscopy in adults; and Apriso, for the maintenance of remission of ulcerative colitis in adults. Its marketing products also include Metozolv ODT orally disintegrating tablets for the relief of symptomatic gastroesophageal reflux or shor... Top Stories| | 2010-03-17 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
| | | 2010-03-15 |  | |
|
| | A rally among airlines and a surprise jump in factory orders pushed US stocks higher in choppy trading on Tuesday. 2010-03-17 |  | |
|
Community Discussions | | | (2.27) | 13.24% |
| CSKI China Sky One Medical Inc. | Trade It Now | | NASDAQ |
| |
Market Cap 247.9M Book Value 7.464 EBITDA 47.3M Year Low 10.21 Year High 25.45 EPS 2.186 P/E 7.85 P/B Ratio 2.30 Short Ratio 3.90 Sector Healthcare Full Time Employees 1,804 Industry Drug Related Products Open 16.15 High 16.41 Low 14.19 Last Close 17.15 Volume 1.3 M Target Price 26.25 Current EPS 2.186 This Year EPS 2.31 Next Year EPS 2.69 Current PE 7.85 This Year PE 7.42 Next Year PE 6.38 China Sky One Medical, Inc.Room 1706 Di Wang Building No 30 Gan Shui Road Nangang District Harbin,
150001 China - Map
Phone: 86 451 5399 4069
Fax: 86 451 8700 6045
Web Site: VisitType: Stock | | China Sky One Medical, Inc., through its subsidiaries, engages in the development, manufacture, marketing, and sale of over-the-counter, branded nutritional supplements, and over-the-counter plant and herb based pharmaceutical and medicinal products primarily in China. |
Company Summary more  China Sky One Medical, Inc., through its subsidiaries, engages in the development, manufacture, marketing, and sale of over-the-counter, branded nutritional supplements, and over-the-counter plant and herb based pharmaceutical and medicinal products primarily in China. The company’s products include sumei slim patch to foster weight loss and prevent weight gain; pain killer patch used for the treatment of various ailments, including fever, headache, dysentery, diarrhea, and stiffness and pain in the neck caused by hypertension; anti-hypertension patch that improves circulation and reduces blood pressure; and dysmenorrheal patch for pain relief from dysmenorrheal in a woman’s critical days, a... China Sky One Medical, Inc., through its subsidiaries, engages in the development, manufacture, marketing, and sale of over-the-counter, branded nutritional supplements, and over-the-counter plant and herb based pharmaceutical and medicinal products primarily in China. The company’s products include sumei slim patch to foster weight loss and prevent weight gain; pain killer patch used for the treatment of various ailments, including fever, headache, dysentery, diarrhea, and stiffness and pain in the neck caused by hypertension; anti-hypertension patch that improves circulation and reduces blood pressure; and dysmenorrheal patch for pain relief from dysmenorrheal in a woman’s critical days, and for regulating pain and catamenia. It also offers yin ke psoriasis spray; wart removing spray; chilblain ointment; hemorrhoids ointment for sterilizing and relieving hemorrhoid symptoms, including itching, distending pain, burning, and bleeding; tinea pedis spray, ointment, and powder for killing various pathogens on the skin surface and subcutaneously, such as mycete, trichopytic, staphylococcal bacteria aureus, bacillus coli, and candida albicans; dermatitis spray; dandruff treatment herbal shampoo; and runze eye drop. In Addition, the company provides cardiac arrest early examination kit, kidney disease testing kit, and early pregnancy test kit, as well as various products made from Chinese herbs and plants, including a leukoderma ointment, rheumatism spray, Coryza powder, Hircus removing spray, gonorrheal cleaning spray, a snoring retardant, deodorants, diet tea, cough arresting patch, pharyngitis spray, clindamycin metronidazole liniment, ganciclovir injection, loquat syrup, and indigowoad root granule. Further, it engages in the sale of medicinal and pharmaceutical products manufactured by others. The company sells its products through pharmaceutical chains. China Sky One Medical, Inc. was founded in 1994 and is headquartered in Harbin, the People’s Republic of China. China Sky One Medical, Inc., through its subsidiaries, engages in the development, manufacture, marketing, and sale of over-the-counter, branded nutritional supplements, and over-the-counter plant and herb based pharmaceutical and medicinal products primarily in China. The company’s products include sumei slim patch to foster weight loss and prevent weight gain; pain killer patch used for the treatment of various ailments, including fever, headache, dysentery, diarrhea, and stiffness and pain in the neck caused by hypertension; anti-hypertension patch that improves circulation and reduces blood pressure; and dysmenorrheal patch for pain relief from dysmenorrheal in a woman’s critical days, a... Top Stories| |
Stocks Movers after Earnings are IVAN, ATU, SMTS, CSKI
Emailwire - 3 hours ago
(EMAILWIRE.COM, March 17, 2010 ) Dallas, Tx - Ivanhoe Energy Inc. (USA) (NASDAQ:IVAN) is down 1.08% to $3.67 after the company reported Q4 loss of $0.04, versus ($0.05) reported for the same ...
2010-03-17 |  | |
| | | 2010-03-17 |  | |
| | |
China Sky One Medical Guides Below Estimates
Trading Markets - 7 hours ago
China Sky One Medical, Inc. (NASDAQ: CSKI) said it expects 2010 revenue of approximately $156.0 million. The current consensus estimate is revenue of $164.5 million for the year ending December 31 ...
2010-03-17 |  | |
| | | 2010-03-17 |  | |
|
Community Discussions |